Lercanidipine

Pharmacologic Class

Antihypertensive; Calcium Channel Blocker; Calcium Channel Blocker, Dihydropyridine

References: International

Álvarez C, Gómez E, Simón M, et al. Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake. Eur J Clin Pharmacol. 2012;68(7):1043-1047.[PubMed 22294059]

Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension.Drugs, 2003;63(22):2449–2472.[PubMed 14609358]

Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J ClinEndocrinol Metab. 2016;101(5):1889-1916.[PubMed 26934393]

Lercanidipine hydrochloride [UK summary of product characteristics]. Devon, United Kingdom: Accord-UK Ltd; June 2019.

Lercanidipine tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199803145. Accessed July 5, 2017.

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the management of arterial hypertension [published online ahead of print December 20, 2013]. Blood Press. 2014;23(1):3-16. doi: 10.3109/08037051.2014.868629.[PubMed 24359485]

Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.[PubMed 23741058]

Zircol (lercanidipine) tablet [product information]. New South Wales, Australia: Alphapharm Pty Limited; March 2018.

Last Updated 8/13/19